Jennifer L. Guerriero, PhD
Jennifer L. Guerriero, PhD Dana-Farber Cancer Institute – Harvard Medical School Modulating the immune system as an anti-cancer strategy has […]
Sheheryar K. Kabraji, BM BCh
Sheheryar K. Kabraji, BM BCh Dana-Farber Cancer Institute – Harvard Medical School While effective HER2-targeting drugs have greatly improved outcomes for […]
Naiara Perurena, PhD
Naiara Perurena, PhD, PharmD Brigham and Women’s Hospital – Harvard Medical School Around 15-20% of breast cancers are characterized by […]
Jan Remsik, PhD PharmD
Jan Remsik, PhD, PharmD Memorial Sloan Kettering Cancer Center Leptomeningeal metastasis (LM), or the spread of tumor cells into the […]
Laura Spring, MD
Laura Spring, MD Massachusetts General Hospital Localized breast cancer patients with higher risk disease are often treated with chemotherapy in […]
Jing Hu, PhD
Jing Hu, PhD Memorial Sloan Kettering Cancer Center Metastasis is a major clinical hurdle in breast cancer treatment, with poor […]
Veerle Daniels, PhD
Veerle Daniels, PhD Dana-Farber Cancer Institute Despite recent advances in treatment options, breast cancer remains the second leading cause of cancer-related […]
Ana Garrido-Castro, MD
Ana Garrido-Castro, MD Dana-Farber Cancer Institute Choosing the best treatments for metastatic breast cancer depends increasingly on molecular features, such as tumor […]
